Nilofabicin
Code | Size | Price |
---|
TAR-T19642-5mg | 5mg | £115.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19642-1mL | 1 mL * 10 mM (in DMSO) | £122.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19642-10mg | 10mg | £135.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19642-25mg | 25mg | £177.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19642-50mg | 50mg | £229.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19642-100mg | 100mg | £334.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Nilofabicin is a potent inhibitor of enoyl-(acyl-carrier-protein) reductase fall(FabI) and can be used in studies about the treatment of complicated acute.
CAS:
934628-27-0
Formula:
C19H20N2O2S
Molecular Weight:
340.44
Pathway:
Microbiology/Virology
Purity:
0.98
SMILES:
Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O
Target:
Antibacterial
References
1. Kim BY, Sohn YT. Solid state of CG-400549, a novel FabI inhibitor: characterization, dissolution, transformation. Arch Pharm Res. 2011 May;34(5):775-9. doi: 10.1007/s12272-011-0511-7. Epub 2011 Jun 9. PubMed PMID: 21656363.
2. Bogdanovich T, Clark C, Kosowska-Shick K, Dewasse B, McGhee P, Appelbaum PC. Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. Antimicrob Agents Chemother. 2007 Nov;51(11):4191-5. Epub 2007 Sep 17. PubMed PMID: 17875997; PubMed Central PMCID: PMC2151435.
3. Yum JH, Kim CK, Yong D, Lee K, Chong Y, Kim CM, Kim JM, Ro S, Cho JM. In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3. Epub 2007 Apr 9. PubMed PMID: 17420210; PubMed Central PMCID: PMC1913239.